Search peptides, terms, sources/
Repair and regeneration

BPC-157

Also known as: Body Protection Compound-157 · Pentadecapeptide BPC 157 · PL 14736

Synthetic gastric-derived peptide studied in animal models of tissue healing. Not licensed in the UK; human evidence is one small uncontrolled study.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. BPC-157 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human observational2 human observational

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide based on a compound isolated from human gastric juice, studied mainly in animal and laboratory models for tissue healing. It is not licensed in the UK, and the only human evidence is one small uncontrolled retrospective study of knee pain.

The animal and laboratory work covers tendon, ligament, muscle and gastrointestinal injury.

Class
Gastric-derived pentadecapeptide
Origin
Fragment / derived
Research areas
Healing & Recovery
UK status
Not licensed in the UK
Best study type
Human observational
Evidence last reviewed

How does BPC-157 work?

In animal and cell studies, BPC-157 is reported to boost nitric oxide signalling, antioxidant genes and the growth of new blood vessels, and to help tendon cells move and survive. These are laboratory findings. A mechanism seen in animals is not proof of the same effect in people.

The mechanism in more detail

Preclinical research describes BPC-157 as acting on several overlapping pathways. It has been shown in animal and in-vitro studies to stimulate nitric oxide synthase and the nitric oxide system, to upregulate antioxidant-related gene expression including heme oxygenase-1, and to activate VEGFR2 signalling associated with the formation of new blood vessels (angiogenesis).

In tendon-fibroblast models, BPC-157 has been shown to increase growth hormone receptor expression and to promote fibroblast outgrowth, survival under stress, and migration, an effect reported to involve the FAK-paxillin signalling pathway.

These are preclinical, mostly animal and in-vitro, mechanistic findings. A proposed mechanism observed in these models is not the same as a demonstrated clinical effect in humans, and independent human evidence for BPC-157 remains limited to a single small, retrospective, uncontrolled observational study (see Research Findings).

Mechanisms and targets

Angiogenesis / VEGFR2 signallingAnti-inflammatory / cytokine modulationGrowth factor receptor upregulation (tendon fibroblasts)Nitric oxide (NO) pathway modulationGrowth hormone receptor (tendon fibroblast expression)Nitric oxide synthase (eNOS)VEGFR2

Classification and structure

Names
BPC-157; Body Protection Compound-157; Pentadecapeptide BPC 157; PL 14736; PL-10; PLD-116
Class
Gastric-derived pentadecapeptide
Origin
Fragment / derived
Structure
15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), molecular weight approximately 1419.
Routes used in the research
Preclinical studies used subcutaneous, intraperitoneal and intragastric or oral routes, depending on the model. The one retrospective human case series used intra-articular injection. This reflects what the cited literature used, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

BPC-157 has 3 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

3 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
12000

Systematic review of 36 studies Limited

Across a systematic review of 36 studies (35 preclinical, 1 clinical), BPC-157 is consistently reported in animal and preclinical models to accelerate healing of tendon, ligament, muscle, bone and gastrointestinal tissue, acting through angiogenic and cell-migration pathways. Independent human clinical evidence supporting the same effect is limited to a single small, uncontrolled retrospective case series.

Study type
Human observational
Population
Predominantly rodent tendon, ligament, muscle, bone and gastrointestinal-injury models; one human retrospective case series
Source
1 Vasireddi et al., 2025

Limitation: The review is preclinical-heavy (35 of 36 included studies are animal models); the sole clinical study is retrospective, uncontrolled and unblinded.

Limitations in full

The review is preclinical-heavy (35 of 36 included studies are animal models); the sole clinical study is retrospective, uncontrolled and unblinded. No RCT or controlled human trial of any kind was identified. The evidence strength is rated Limited for these reasons.

Uncontrolled knee-pain case series Limited

In a 1-year retrospective chart review of 16 patients with chronic knee pain treated at a US clinic, 12 patients received intra-articular BPC-157 alone; 11 of 12 (91.6%) reported significant improvement in knee pain sustained beyond 6 months. No control group, no validated outcome measures and no imaging confirmation of structural change were used.

Study type
Human observational
Population
Human, retrospective chart review, n=12 (BPC-157-only subgroup of a 16-patient cohort)
Source
2 Lee et al., 2021

Limitation: Retrospective, unblinded, no control arm, no validated pain or function scoring, no imaging, small n, single centre.

Limitations in full

Retrospective, unblinded, no control arm, no validated pain or function scoring, no imaging, small n, single centre. This is the only published human study of intra-articular BPC-157 identified. The evidence strength is rated Limited for these reasons.

Registered Phase I, no results Preliminary

A registered Phase I safety and pharmacokinetic trial of BPC-157 (PCO-02, sponsor PharmaCotherapia d.o.o.) in 42 healthy volunteers aged 18 to 35 was registered on ClinicalTrials.gov in December 2015. The sponsor withdrew submission of results in 2016 and no data were ever published. This documents that a trial existed and was registered; it is not evidence of a finding.

Study type
Clinical trial registry entry
Population
Human, healthy volunteers, n=42 planned; results never reported
Source
3 ClinicalTrials.gov

Limitation: No results were ever published; the reason for non-publication is not stated on the public registry and could not be independently confirmed.

Limitations in full

No results were ever published; the reason for non-publication is not stated on the public registry and could not be independently confirmed. Documents a trial's registration and non-completion status only, not a scientific result.

What safety findings have been reported?

2 safety findings are recorded for BPC-157. A short list does not mean a substance is safe; it reflects what has been studied and reported.

FDA compounding category status

The FDA's Pharmacy Compounding Advisory Committee process placed BPC-157 in Category 2 (bulk drug substances that may present significant safety risks) from September 2023, citing concerns about immunogenicity risk with certain routes of administration and complexities in characterising peptide-related impurities. In April 2026 the FDA is reported to have removed BPC-157 from Category 2 following withdrawal of its nomination, but it was not moved to the permitted Category 1 list and remains unapproved with no USP/NF monograph.

Source
4 FDA

Long-term human safety unknown

A 2025 peer-reviewed literature and patent review states BPC-157's long-term human safety profile is unknown. Theoretical safety concerns raised in the literature include the possibility that BPC-157's angiogenic activity could support growth of an undetected tumour, that its proline metabolite could theoretically generate reactive oxygen species, and that high local nitric oxide levels could interfere with cytochrome P450 function. The same review states no toxic dose has been established in animal studies and reports isolated cases of pain and tissue necrosis with aqueous injection.

Source
5 Jozwiak et al., 2025

What is BPC-157's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for BPC-157.
Prescription status
Not applicable, there is no licensed product to classify as POM, P, or GSL.
Medicine class
Not classified as a licensed medicine.
MHRA position
Not a controlled substance under the Misuse of Drugs Act 1971. Whether a specific product is a medicinal product under the Human Medicines Regulations 2012 is determined case-by-case by the MHRA based on presentation and claims made. No BPC-157-specific MHRA determination notice or Yellow Card FOI data was located.
Authorised use
None.
Other restrictions
In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names BPC-157 under S0, non-approved substances, prohibited at all times.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. BPC-157 is recorded as not licensed in the UK (checked 14 November 2026).

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine, A Systematic Review. HSS Journal (The Musculoskeletal Journal of Hospital for Special Surgery)Systematic review · DOI 10.1177/15563316251355551 · PMID 40756949 · Original ↗
  2. Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and MedicineHuman observational · PMID 34324435 · Original ↗
  3. ClinicalTrials.gov A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PCO-02 (BPC-157) in Healthy Volunteers. ClinicalTrials.govClinical trial registry entry · Original ↗
  4. FDA Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. U.S. Food and Drug Administration (FDA) · Original ↗
  5. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. Pharmaceuticals (Basel), MDPINarrative review · DOI 10.3390/ph18020185 · Original ↗
  6. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about BPC-157

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide based on a compound isolated from human gastric juice, studied mainly in animal and laboratory models for tissue healing. It is not licensed in the UK, and the only human evidence is one small uncontrolled retrospective study of knee pain. Read what it is.

Is BPC-157 licensed in the UK?

PeptGuru records BPC-157's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on BPC-157 show?

PeptGuru records 3 research findings for BPC-157: a systematic review of 36 studies (35 in animals, 1 in people), one small uncontrolled study in people, and a registered trial that never published results. No controlled human trial was identified. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for BPC-157?

2 safety findings are recorded, including: FDA compounding category status; long-term human safety unknown. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for BPC-157?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · Removed an unsourced statement about how BPC-157 is sold in the UK. The same unsourced statement was removed from ten other profiles.
  • Regulatory update · UK status now cites a dated MHRA database check. Sport status confirmed from WADA's own 2026 Prohibited List (S0).

How findings are graded: the grading method. All changes.

  • TB-500Thymosin Beta-4 fragment

    Short synthetic fragment linked to thymosin beta-4. Not licensed in the UK. No human trials of TB-500 itself were found; trials of the full-length protein are not evidence for it.

    Repair and regenerationAnimal studiesEvidence reviewed
    LimitedNot licensed in the UK
  • GHK-CuCopper peptide GHK

    Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Thymosin beta-4Thymosin β4

    Natural 43-amino-acid peptide studied in eye and wound-healing trials. Not licensed in the UK. Trials were small with mixed results. It is not TB-500.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK

Compare BPC-157 with TB-500

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.